NorthWest Biotherapeutics Inc (NWBO)

[kabunushi]

The market is more than capable of understanding the annual patient numbers for nGBM and rGBM, assigning a projected market penetration curve to a new SOC, and making rough estimates from various inputs as to likely selling price and gross margins. Those estimates go up or down over time, but for sure a company like NWBO would get a radical upwards valuation if it were trading at .70 when any single RA approval gets announced (assuming no radical revaluation has occurred in the meantime, which seems unlikely)..

Unless a buyout happens, the stock price certainly can lag what longs know to be a fair value range at any point on the road to large financial success. To get really reasonable prices for the stock longs might have to wait but please don't try to tell us that there aren't going to be a lot of new buyers until not only RA but not even until the company is profitable. That's basically nuts - tiny cap biotech doesn't work that way.